Literature DB >> 16044577

Fanconi syndrome associated with use of tenofovir in HIV-infected patients: a case report and review of the literature.

David Quimby1, Maximo O Brito.   

Abstract

We report a case of Fanconi syndrome associated with the use of tenofovir disoproxil fumarate, a nucleotide reverse transcriptase inhibitor used in the treatment of HIV infection. A 56-year-old HIV-infected man was admitted to the hospital with a chief complaint of severe, progressive weakness. His HIV infection was well controlled by antiretroviral therapy; other medical problems included hepatitis C and chronic renal insufficiency. About 2 weeks before presentation, the patient had received an influenza vaccination, which was followed by a generalized viral syndrome of several days' duration. Next, weakness developed and culminated in an inability to walk; this prompted the patient's presentation at the hospital. Urine chemistry, electrolyte panel, and clinical presentation were consistent with Fanconi syndrome, a generalized proximal tubular dysfunction involving proteins, glucose, uric acid, and electrolytes. Along with our Case Report, we review 25 cases of Fanconi syndrome previously reported in the literature.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16044577

Source DB:  PubMed          Journal:  AIDS Read        ISSN: 1053-0894


  11 in total

1.  Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B.

Authors:  N Gara; X Zhao; M T Collins; W H Chong; D E Kleiner; T Jake Liang; M G Ghany; J H Hoofnagle
Journal:  Aliment Pharmacol Ther       Date:  2012-04-16       Impact factor: 8.171

2.  In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells.

Authors:  Francesc Vidal; Joan Carles Domingo; Jordi Guallar; Maria Saumoy; Begoña Cordobilla; Rainel Sánchez de la Rosa; Marta Giralt; Maria Luisa Alvarez; Miguel López-Dupla; Ferran Torres; Francesc Villarroya; Tomas Cihlar; Pere Domingo
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

Review 3.  Update on tenofovir toxicity in the kidney.

Authors:  Andrew M Hall
Journal:  Pediatr Nephrol       Date:  2012-08-10       Impact factor: 3.714

Review 4.  Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?

Authors:  Jérôme Tourret; Gilbert Deray; Corinne Isnard-Bagnis
Journal:  J Am Soc Nephrol       Date:  2013-09-19       Impact factor: 10.121

Review 5.  Water, electrolytes, and acid-base alterations in human immunodeficiency virus infected patients.

Authors:  Carlos G Musso; Waldo H Belloso; Richard J Glassock
Journal:  World J Nephrol       Date:  2016-01-06

Review 6.  Tenofovir and bone health.

Authors:  Philip M Grant; Aoife G Cotter
Journal:  Curr Opin HIV AIDS       Date:  2016-05       Impact factor: 4.283

7.  Renal safety of tenofovir containing antiretroviral regimen in a Singapore cohort.

Authors:  Arlene C Chua; Ryan M Llorin; Kelvin Lai; Philippe Cavailler; Hwa Lin Law
Journal:  AIDS Res Ther       Date:  2012-06-15       Impact factor: 2.250

8.  An update on the use of Atripla in the treatment of HIV in the United States.

Authors:  Michael A Horberg; Daniel B Klein
Journal:  HIV AIDS (Auckl)       Date:  2010-06-18

9.  Impact of nucleos(t)ide analogue combination therapy on the estimated glomerular filtration rate in patients with chronic hepatitis B.

Authors:  Xun Qi; Jinyu Wang; Liang Chen; Yuxian Huang; Yanli Qin; Richeng Mao; Jiming Zhang
Journal:  Medicine (Baltimore)       Date:  2015-04       Impact factor: 1.889

10.  Tenofovir is associated with increased tubular proteinuria and asymptomatic renal tubular dysfunction in Ghana.

Authors:  David R Chadwick; Fred S Sarfo; Elaine S M Kirk; Dorcas Owusu; George Bedu-Addo; Victoria Parris; Ann Lorraine Owusu; Richard Phillips
Journal:  BMC Nephrol       Date:  2015-12-01       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.